Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
AssigneeCsl Behring Lengnau AG
InventorsSabine PESTEL, Elmar RAQUET, Thomas WEIMER
Life of this patent
Estimating the term…
Abstract
The invention pertains to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment or prophylaxis of a blood coagulation disorder, said treatment or prophylaxis comprising administering the recombinant polypeptide and a Factor VIII protein (FVIII) extravascular to a subject having a blood coagulation disorder, wherein said recombinant polypeptide is capable of binding to said FVIII, and wherein the molar ratio of the recombinant polypeptide to be administered to the FVIII to be administered is higher than 50.
Claims30
A method for the treatment or prophylaxis of a blood coagulation disorder, comprising administering an effective amount of (i) a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) and (ii) Factor VIII protein (FVIII) to a subject having a blood coagulation disorder,
- wherein at least one of the recombinant polypeptide and the FVIII is administered extravascularly,
- wherein said recombinant polypeptide is capable of binding to said FVIII, and
- wherein the molar ratio of the recombinant polypeptide to the FVIII is higher than 50.
(canceled)
A pharmaceutical composition comprising
- (i) a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF), and
- (ii) a Factor VIII protein (FVIII);
- wherein the molar ratio of the recombinant polypeptide to the FVIII is greater than 50,
- wherein said recombinant polypeptide is capable of binding to said FVIII, and
- wherein the pharmaceutical composition is formulated for extravascular co-administration of the recombinant polypeptide and the FVIII.
A pharmaceutical kit comprising (i) a first composition comprising a Factor VIII protein (FVIII) and (ii) a second composition comprising a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF), wherein the molar ratio of the recombinant polypeptide to the FVIII is greater than 50,
- wherein the recombinant polypeptide is capable of binding to the FVIII, and
- wherein the recombinant polypeptide and the FVIII are formulated for extravascular co-administration.
Dependencies are inferred from the claim text.